IRIDEX Reports Q3 2026 Revenue Decline Amid International Headwinds and Lowered Guidance
IRIDEX (IRIX) reported third-quarter revenue of $10.2 million, a 19% decline compared to the previous year. The decrease was primarily driven by challenges in international retina markets, regulatory delays in India, and economic headwinds in China, which saw order activity drop from $4 million to $400,000 year-to-date. Despite the top-line contraction, the company achieved significant gross margin expansion to 42.4%, up from 32.1% last year, due to pricing discipline and the absence of prior inventory write-offs. The company has lowered its full-year revenue guidance to a range of $46 million to $48 million, down from the previous estimate of $51 million to $53 million. While international markets faced volatility, U.S. PASCAL sales grew 50% year-over-year. IRIDEX also completed its manufacturing relocation to San Jose, which is expected to yield $600,000 in annualized rent savings.

Tickers: $IRIX
Topics: gross margin improvement guidance downgrade inventory management net loss revenue decline